In defense delivery pace and inventory decide growth quality
Israeli defense exports reached a new record, but the TASE question is not who is linked to defense. It is who can convert orders, development projects and grants into serial production, gross profit and cash.
Israeli defense exports reached another record, $19.2 billion in 2025 according to the Ministry of Defense. That is a strong headline, but it is not enough for stock analysis. The local market question is shifting from demand to delivery: who has production lines, who is still in development, who receives advances, who needs to build inventory, and who can preserve gross margin as orders grow. The procurement and export wave is real, but it also increases pressure on the supply chain. The important distinction is not defense versus non-defense companies. It is companies already selling and delivering versus companies still at the trial, grant or first-order stage.
Backlog Is Only The Starting Point
Elbit Systems is the large reference point. When a company like Elbit holds major backlog and keeps winning contracts, the challenge is less demand and more execution: labor, subcontractors, inventory, export approvals, delivery dates and cash. The same logic applies to smaller companies. A defense contract looks good in the headline, but the report must answer three questions: when is it delivered, what is the margin, and when is cash received.
Next Vision, Ariit, Reshef, Bet Shemesh, Ashot, RP Optical, TAT Technologies and Smart Shooter sit in the layer where products, customers or clear orders already exist. Their key issue is conversion of backlog into revenue and cash. If inventory and receivables grow at a reasonable pace and are supported by advances or good collection, growth quality is higher. If working capital stretches, growth may require more financing.
Not Every Order Is The Same
Four event types should be separated. The strongest is a binding supply contract with quantity, price and timetable. Next is a framework or first order that can open a recurring line. Below that sit development work and operational trials. Grants are another category. All can be positive, but their financial meaning is very different.
Solorom, Imco, Aran R&D, Autonomous, RSL, Third Eye, Axon Vision, Valorix, DSIT, Odysight and Aerodrome belong in the broader watchlist. Some have interesting products or defense customers, but they are not all at the same proof level. A successful trial is not the same as serial delivery. A grant is not the same as a recurring order with an advance.
| Proof level | Example companies | What matters |
|---|---|---|
| Proven production and backlog | Elbit, Next Vision, Ariit, Reshef, Bet Shemesh, Ashot, RP Optical | Deliveries, gross margin, inventory, collections and advances |
| First order or emerging line | Smart Shooter, Aran, Solorom, Imco, Autonomous, RSL | Follow-on orders, capacity use and payment terms |
| Development, trial or grant | Third Eye, Axon Vision, Valorix, Odysight, Aerodrome | Conversion into binding contract and serial price |
Where Demand Becomes Pressure
The defense sector can grow strongly and still pressure the balance sheet. Production requires inventory, employees, quality testing, guarantees, components and sometimes customer credit. If the customer pays an advance, expansion is easier to fund. If payment comes only after delivery, the order can look impressive while requiring interim financing.
That is why FMS, Israel Shipyards where relevant, Mer, ImageSat and TSG should be judged by their specific model rather than by the defense label. Armor materials, electro-optics, defense software, satellites and vessels are different businesses with different sales cycles, inventory needs, export approvals and payment terms.
The conclusion is that the defense wave is real, but the TASE thesis sits in operating detail. The next reports should be read less for the word "defense" and more for backlog, delivery, advances, inventory, receivables, gross margin and operating cash flow. Companies that deliver and collect on time can show higher-quality growth. Companies still in development or funding large orders from thin balance sheets will need to prove more.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.